<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Leveraging</title>
	<atom:link href="http://www.tapanray.in/tag/leveraging/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Covid Prompts Pharma To Move Away From Competition Driven Business Model</title>
		<link>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-prompts-pharma-to-move-away-from-competition-driven-business-model</link>
		<comments>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/#comments</comments>
		<pubDate>Mon, 26 Oct 2020 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dying]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-serving]]></category>
		<category><![CDATA[solo]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trademark]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10304</guid>
		<description><![CDATA[As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a &#8230; <a href="http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma To Leverage The Art of Turning Challenges Into Opportunities, Now</title>
		<link>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now</link>
		<comments>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/#comments</comments>
		<pubDate>Mon, 20 Jul 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[respelling]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[turning]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10179</guid>
		<description><![CDATA[Since, the dawn of the year 2020, the human population living in different countries, across the world are facing ‘lockdowns in different forms. Although essential, it severely restricts normal daily essential and other important activities of all. A large number &#8230; <a href="http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game is Changing: Ensure Better Treatment Outcomes: Leverage Technology</title>
		<link>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology</link>
		<comments>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/#comments</comments>
		<pubDate>Mon, 03 Jun 2019 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[augmentation]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Digihaler]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[non-drug]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[ProAir]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replacement]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[types]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9570</guid>
		<description><![CDATA[Today, several pharma players, mostly ‘encouraged’ by many non-pharma tech companies, are trying to gain, at least, a toehold in the digital health care space. It is visible even within the generic drug industry. Such initiatives, as they gain a &#8230; <a href="http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Patient Compliance To Boost Pharma Sales…And More…</title>
		<link>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-patient-compliance-to-boost-pharma-salesand-more</link>
		<comments>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/#comments</comments>
		<pubDate>Mon, 20 May 2019 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[apps]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[drug companies]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[new products]]></category>
		<category><![CDATA[non-adherence]]></category>
		<category><![CDATA[noncompliance]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[patient-compliance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9534</guid>
		<description><![CDATA[One high-impact area in the healthcare space that often finds its place in the backseat is &#8211; patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course &#8230; <a href="http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SCM: Embracing Technology For Patients’ Safety</title>
		<link>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scm-embracing-technology-for-patients-safety</link>
		<comments>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/#comments</comments>
		<pubDate>Sun, 17 Dec 2017 23:40:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[D-Cold]]></category>
		<category><![CDATA[DGFT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DSCSA]]></category>
		<category><![CDATA[embracing]]></category>
		<category><![CDATA[harnessing]]></category>
		<category><![CDATA[identifier]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[SCM]]></category>
		<category><![CDATA[serialization]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[trace]]></category>
		<category><![CDATA[Track]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8646</guid>
		<description><![CDATA[Supply Chain Management (SCM) in the pharma industry is generally perceived as a logistic function, just in most other industries, involving the distribution of medicines from manufacturing plants, right up to pharma distributors. Thereafter, it becomes the responsibility of the &#8230; <a href="http://www.tapanray.in/scm-embracing-technology-for-patients-safety/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scm-embracing-technology-for-patients-safety/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leveraging Artificial Intelligence For Greater Patient-Centricity</title>
		<link>http://www.tapanray.in/leveraging-artificial-intelligence-for-greater-patient-centricity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-artificial-intelligence-for-greater-patient-centricity</link>
		<comments>http://www.tapanray.in/leveraging-artificial-intelligence-for-greater-patient-centricity/#comments</comments>
		<pubDate>Sun, 10 Dec 2017 23:25:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8620</guid>
		<description><![CDATA[‘Artificial Intelligence (AI)’ – the science of simulation of intelligent behavior in computers, has the potential to leave a transformational impact on virtually everything that we see and feel around us. As many will know, the modern definition of AI &#8230; <a href="http://www.tapanray.in/leveraging-artificial-intelligence-for-greater-patient-centricity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-artificial-intelligence-for-greater-patient-centricity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multi-channel Engagement: A New Normal In Pharma Marketing</title>
		<link>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multi-channel-engagement-a-new-normal-in-pharma-marketing</link>
		<comments>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/#comments</comments>
		<pubDate>Mon, 26 Dec 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8021</guid>
		<description><![CDATA[The 2015 Report of AffinityMonitor reconfirms that access to important doctors for pharma Medical Representatives (MRs) continues to decline. Now, fewer than half of all doctors are truly accessible to the MRs, down from nearly 80 percent in 2008. In &#8230; <a href="http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leveraging 3D Printing In Pharma, For Cost Containment And Patient-Centricity</title>
		<link>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity</link>
		<comments>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/#comments</comments>
		<pubDate>Mon, 06 Jun 2016 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[printing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7662</guid>
		<description><![CDATA[Today, although a number of new and state of the art drugs is regularly being developed, and brought to the market at a reasonably rapid pace, their access to the majority of the global population has still remained a huge &#8230; <a href="http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
